drugset / Trial / NCT00913458

Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis

NCT00913458 ↗

Phase 4 Completed 306 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study to evaluate whether there is sustained remission and productivity in subjects with early rheumatoid arthritis started on etanercept plus methotrexate treatment.

Timeline

Start
2009-09
Primary completion
2012-06
Completion
2012-12

Outcome

Met primary endpoint

paper More patients in the combination-therapy group than in the methotrexate-alone group or the placebo group met the criterion for the primary end point PMID 25372086 ↗

paper P=0.009 for combination therapy vs. methotrexate alone; P<0.001 for combination therapy vs. placebo PMID 25372086 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg —
Subject Etanercept Protein / enzyme biologic 50 mg —

Indications